No Data
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript
Mediwound's Promising Outlook: Expansion and Trials Support Buy Rating
MediWound Advances With FDA Approval and New Funding
MediWound Ltd. Advances Development With EscharEx IND Submission Planned for Year-End and NexoBrid FDA Pediatric Approval
MediWound Q3 2024 GAAP EPS $(0.98) Misses $(0.45) Estimate, Sales $4.36M Miss $6.01M Estimate